XML 76 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Segment information (Tables)
12 Months Ended
Dec. 31, 2024
Segment information  
Schedule of segment financial information

The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):

​

​

​

​

​

​

​

Year Ended December 31, 

​

2024

    

2023

Collaboration revenue

$

9,041

​

$

14,018

Less:

​

​

​

​

​

In-process research and development

​

(152,344)

​

​

(80,802)

Direct research and development expenses(1)

​

​

​

​

​

Varegacestat

​

(27,954)

​

​

—

IM-1021

​

(24,130)

​

​

—

IM-3050

​

(13,359)

​

​

—

Other

​

(35,335)

​

​

(11,278)

Indirect research and development(2)

​

(28,764)

​

​

(11,811)

General and administrative(3)

​

(32,955)

​

​

(19,657)

Total operating expenses

​

(314,841)

​

​

(123,548)

Loss from operations

​

(305,800)

​

​

(109,530)

Interest income

​

12,837

​

​

2,724

Net loss

$

(292,963)

​

$

(106,806)